Eli Lilly’s Next-Generation Weight-Loss Shot Clears Anoth…

Eli Lilly & Co. announced that its next-generation weight-loss drug, retatrutide, shows no increase in overall heart risk according to a new study. This trial focused on cardiovascular safety in patients with obesity and heart disease, addressing previous concerns about possible heart rhythm abnormalities. The latest findings, along with another study involving patients with obesity and diabetes, suggest a strong potential for this drug to become a blockbuster in the weight-loss market.

Weight-Loss Drugs:

A $1 Trillion GLP-1 Giant

BackForward

Health

FacebookXLinkedIn

EmailLink

Gift

FacebookXLinkedIn

EmailLink

GiftGift this article

Confidential tip?\ Send a tip to our reporters

Site feedback:\ Take our SurveyNew Window

FacebookXLinkedIn

EmailLink

Gift

By Madison Muller

July 23, 2026 at 10:45 AM UTC

Updated on July 23, 2026 at 12:50 PM UTC

BookmarkSave

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it nears regulatory review.

Lilly’s trial evaluated retatrutide’s cardiovascular safety in people with obesity and heart disease after earlier studies raised questions about a possible increase in heart rhythm abnormalities. The latest findings — plus another new study in patients with obesity and diabetes — help solidify the drug’s blockbuster potential.

Read Original at Bloomberg.com →

Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle